REPORT HIGHLIGHT
Immunohistochemistry market was valued at USD 1.77 billion by 2019, growing with 7.3% CAGR during the forecast period, 2020-2026
Market Dynamics
The introduction of novel technologically advanced immunohistochemistry solutions, growing prevalence of chronic diseases, and an increase in drug discovery are some of the major factors driving the growth of global immunohistochemistry market. In addition, growing healthcare expenditure and rising geriatric population are other factors fuelling market growth. According to statistics provided by the World Health Organization (WHO), the geriatric population all across the globe is estimated to reach around 2 billion by the end of 2050. Furthermore, increasing demand for personalized medicine and rapid growth in the emerging economies across Latin America and APAC are likely to create lucrative opportunities in the overall market during the forecast period. However, high setup costs and lack of specificity associated with immunohistochemistry techniques are expected to hinder the market growth in the coming future.
The antibodies segment accounted for the majority of share in the market in 2019 and is estimated to grow at a healthy rate during the forecast period. This is majorly owing to their extensive usage in immunohistochemistry procedures for drug testing and disease diagnosis. Antibody-related products such as antibody-drug conjugates, Fc-fusion proteins, & anti-body fragments and therapeutic monoclonal antibodies have become the chief product class in the overall market. Along with antibodies, the kit segment is projected to grow at the fastest pace by 2030 owing to the convenience and the compact nature offered by them. In addition, the kits used in immunohistochemistry consist of numerous products that are customized to fit the needs of the clinicians.
The diagnostics segment registered for the largest share in the industry in 2019 and is projected to experience a lucrative growth rate in the projected timeframe. The growth of this segment is attributed to the increase in the prevalence of chronic diseases and the increasing demand for an accurate diagnosis. Moreover, the increasing research & developments by pharmaceutical companies for novel drug development and discovery is estimated to raise demand for immunohistochemistry solutions. The PhRMA (Pharmaceutical Research & Manufacturers of America) invested around USD 79.6 billion in 2018 for the development and discovery of novel medicines.
Hospitals and diagnostic laboratories accounted for majority market share in 2019 majorly due to an increase in the incidence of chronic diseases coupled with the growing demand for disease diagnosis. Besides, technological advancements such as digital pathology and automated sample preparation have added considerable value. In addition, the growth in the number of clinical research laboratories and hospitals has also surged the demand for diagnostics, thereby boosting the segmental growth.
The North America region is estimated to hold a dominant position in terms of revenue and is anticipated to continue to lead the immunohistochemistry market during the period of forecast. The dominance of this region is attributed to the presence of well-established healthcare infrastructure coupled with the increasing adoption of immunohistochemistry in diagnostic centres and laboratories. The Asia Pacific market for immunohistochemistry is projected to witness the highest growth due to rapid economic development in emerging countries such as India, China, Singapore, and South Korea. In addition, the high prevalence of chronic diseases and a rapidly aging population are also anticipated to be prominent factors propelling the regional market growth.
Key players of the market include:
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• Bio SB
• Bio-Rad Laboratories, Inc.
• Perkinelmer, Inc.
• Cell Signaling Technology, Inc.
• Abcam plc
The market size and forecast for each segment and sub-segments has been considered as below:
• Historical Year – 2015 to 2018
• Base Year – 2019
• Estimated Year – 2020
• Projected Year – 2026
TARGET AUDIENCE
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT
? Kits
? Reagents
o Fixation Reagents
o Stabilizers
o Organic Solvents
o Proteolytic Enzymes
o Histological Stains
o Blocking Sera and Reagents
o Chromogenic Substrates
o Diluents
? Antibodies
o Primary Antibodies
o Secondary Antibodies
? Equipment
o Tissue Processing Systems
o Slide Scanners
o Slide Staining Systems
o Tissue Microarrays
o Others
GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION
? Diagnostics
o Diabetes Mellitus
o Cardiovascular Diseases
o Autoimmune Diseases
o Cancer
o Infectious Diseases
o Nephrological Diseases
? Brain & Neurology
? Drug Testing
? Ophthalmology
? Others
GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY END USE
? Research Institutes
? Hospitals
? Diagnostic Laboratories
? Others
GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY REGION
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA